Alfa® -The Omega 3 experience applied to gastrointestinal diseases
Alfa® is an oral formulation of highly purified eicosapentaenoic acid free fatty acid (FFA) that is under development for the Chemoprevention of hereditary colon cancer caused by familial adenomatous polyposis (FAP)
Alfa® is a joint development between KD Biopharma and SLA Pharma AG, a Swiss specialty pharmaceutical company focussed on new drugs for the treatment of gastrointestinal disorders. With a global network of top gastroenterologists and colorectal surgeons SLA Pharma AG has a proven track record of commercializing products from concept to market application.
Alfa® has successfully completed Phase I & II studies and has started its Phase III trial in the EU. Both, in the EU and in the USA the drug has been granted the “orphan drug designation”. With successful completion of the Phase III trial and subsequent designation of the “orphan drug status”, Alfa® will be granted a 7 (USA) and 10 year (EU) market exclusivity as orphan drug. Further market protection up to 2027 is ensured by several patent applications recently filed.
KD Biopharma owns all rights to Alfa® and is presently identifying national and international out-licensencing partners specialized in the GI sector.